



PARKINSON'S DISEASE NEWS

<http://www.viartis.net/parkinsons.disease/news.htm>

4th August 2013 - New research

CLINICAL TRIAL OF AFQ056 FOR DYSKINESIA

Movement Disorders [2013] July 11 [Epub ahead of print] (Stocchi F, Rascol O, Destee A, Hattori N, Hauser RA, Lang AE, Poewe W, Stacy M, Tolosa E, Gao H, Nagel J, Merschhemke M, Graf A, Kenney C, Trenkwalder C.)

AFQ056 is a new glutamate receptor antagonist being developed for the treatment of L-dopa induced dyskinesia. Dyskinesia is a difficulty or distortion in performing voluntary movements, which often occurs as a side effect of long term therapy with L-dopa. For more information go to Dyskinesia. People with Parkinson's Disease were given either 20mg, 50mg, 100mg, 150mg, or 200mg daily for 12 weeks. The primary outcome in order to assess the effect on dyskinesia was the modified Abnormal Involuntary Movements Scale.

Patients taking 200mg AFQ056 daily demonstrated significant improvements on the modified Abnormal Involuntary Movements Scale. There was a dose-response relationship, with 200 mg daily demonstrating the greatest effect. However, no significant changes were observed on the 26-item Parkinson's Disease Dyskinesia Scale or the Patient's / Clinician's Global Impression of Change. Unified Parkinson's Disease Rating Scale part III scores were not significantly changed, indicating no worsening of motor symptoms. The most common adverse events were dizziness, hallucination, fatigue, nasopharyngitis, diarrhea, and insomnia. These results can guide the selection of doses for future clinical trials.

<http://www.viartis.net/parkinsons.disease/news/130804.pdf>

mail@viartis.net

©2013 Viartis